Beam Therapeutics Inc (BEAM) is a leading biotechnology business based in the US. Strong Sell. JPMorgan Chase & Co.‘s price target points to a potential upside of 0.11% from the […] Beam Therapeutics Inc. (NASDAQ:BEAM)’s stock price traded up 7.2% during mid-day trading on Monday . Most Recent Rating . Monday, January 27, 2020. Looking at the price targets, the low is -59.34% off current price level while to achieve the yearly target high, price needs to move +40.37%. 662,801 shares were traded during trading, a decline of 39% from the average session volume of 1,090,246 shares. The stock traded as high as $98.87 and last traded at $98.63. All prices are listed in US Dollars. Beam Therapeutics Inc. (BEAM) estimates and forecasts The stock had previously closed at $85.00. The brokerage set an “overweight” rating and a $145.00 price target on the stock. Wells Fargo & Company‘s target price points to a potential upside of 38.10% from the stock’s current price. Analysts have given the company’s stock an average 52-week price target of $83.83, forecast between a low of $42 and high of $145. Analysts covering Beam Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.014 for the next financial year. The price target was set to $38.00 → $100.00. Wedbush increased their price target on Beam Therapeutics from $42.00 to $112.00 in a report on Thursday. BEAM updated stock price target summary. BEAM lost -$3.10 per share the over the last 12 months. Short-term and long-term BEAM (Beam Therapeutics Inc) stock price predictions may be different due to the different analyzed time series. It opened the day at $75.31 after a previous close of $71.28. 01/05 06:30. Yahoo. Beam Therapeutics Inc Stock Price Forecast for 2026: February 2026: Open: 1021.200: Close: 1034.000: Min: 1021.200: Max: 1034.020: Change: 1.24 % > Page 2: detailed data / stock price table . Hold. Beam Therapeutics (NASDAQ:BEAM) had its price target hoisted by Wedbush from $42.00 to $112.00 in a research report released on Thursday, The Fly reports. Beam Therapeutics is a preclinical stage biopharma with a $3.3B market cap and a recent IPO whose chart looks like this:Source. 07:59 AM ET. The projected low price target is $47 while the price target rests at a high of $145. This price target is based on 4 analysts offering 12 month price targets for Sorrento Therapeutics in the last 3 months. Barclays cut shares of Beam Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $47.00 to $90.00 in a research report on Monday. Several other research firms also recently issued reports on BEAM. JPMorgan Chase & Co. does not see either upside or downside right now giving BEAM "Overweight - Neutral" on their last update on January 29, 2021. It is also 50.84% off the consensus price target high of $145.00 offered by 7 analysts, but current levels are 15.14% higher than the price target low of $84.00 for the same period. BEAM is down -$7.79 from the previous closing price of $88.67 on volume of 1,154,499 shares. $90.40 +7.93%. Beam Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. $145.00 +73.11%. Globe Newswire. In depth view into Beam Therapeutics Price including historical data from 2020, charts, stats and industry comps. Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Avg Forecast. Beam Therapeutics started at overweight with $31 stock price target at J.P. Morgan MarketWatch. --Analyst Actions: Stifel Starts Beam Therapeutics at Hold With $84 Price Target. Seeking Alpha Catalyst Watch. 1 analysts 20%. Shares in Beam Therapeutics Inc are currently priced at $105. 1 analysts 20%. They currently have a $100.00 target price on the stock. The company’s stock price has collected -8.33% of loss in the last five trading sessions. The new note on the price target was released on March 02, 2020, representing the official price target for Beam Therapeutics Inc. stock. Beam Therapeutics Inc. (NASDAQ:BEAM) shares rose 16% during mid-day trading on Thursday . More Buy. Stifel Nicolaus initiated coverage on Beam Therapeutics in a report on Tuesday, January 5th. The BEAM stock was last observed hovering at around $72.60 in the last trading session, with the day’s loss setting it -1.32% off its average median price target of $95.00 for the next 12 months. Max Forecast. The stock traded as high as $97.33 and last traded at $95.58. Use the tables below to see what analysts covering Beam Therapeutics Inc think about its future price and what recommendations they have for investors and traders. Wells Fargo & Company assumed coverage on shares of Beam Therapeutics in a research report on Tuesday, February 16th. Click Here to get the full report on Beam Therapeutics Inc (BEAM) Stock. Barclays cut Beam Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $47.00 to $90.00 in a report on Monday. 12/24 13:15. The average price target is $28.75, with a high forecast of $35.00 and a low forecast of $24.00. $33.00-60.6%. BEAM: Get the latest Beam Therapeutics stock price and detailed information including BEAM news, historical charts and realtime prices. At that level they are trading at 31.81% premium to the analyst consensus target price of 0.00. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Beam Therapeutics with a $109.67 average price target, a 7.2% upside from current levels. Beam Therapeutics Inc. (BEAM) estimates and forecasts. Strong Buy. Beam Therapeutics (NASDAQ:BEAM) was downgraded by equities researchers at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research note issued on Friday, Briefing.com reports. Press Release reported 13 hours ago that Beam Therapeutics Announces Acquisition of Guide Therapeutics. Several analysts have […] Beam Therapeutics started at outperform with $32 stock price target at Wedbush MarketWatch. Analysts on Wall Street suggest a consensus price target of $83.83, implying a decline of -21.25% to the stock’s current value. In that case, then, we find that the current price level is +62.68% off the targeted high while a plunge would see the stock lose -47.27% from current levels. Find the latest Beam Therapeutics Inc. (BEAM) stock quote, history, news and other vital information to help you with your stock trading and investing. The latest price was $84.02 (25 minute delay). The new note on the price target was released on August 05, 2020, representing the official price target for Beam Therapeutics Inc. stock. Home Analyst Ratings Stifel initiates Beam Therapeutics at Hold rating with $84 price target. 3 analysts 60%. 01/06 07:53. The average price target represents a 228.20% upside from the last price of $8.76. Further, Beam Therapeutics Inc. (BEAM) has a beta value of 0, and an average true range (ATR) of 10.11. Previously, the target price had yet another raise to $32, while Wedbush analysts kept a Outperform rating on BEAM stock. --Analyst Actions: Wells Fargo Starts Beam Therapeutics at Overweight With $145 Price Target 7:13AM ET 2/16/2021 MT Newswires (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Find real-time BEAM - Beam Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Previously, the target price had yet another raise to $31, while JP Morgan analysts kept a Overweight rating on BEAM stock. Get the hottest stocks to trade every day before the … Beam Therapeutics Inc (NASDAQ: BEAM) acquires Guide Therapeutics (GuideTx), a developer of nonviral drug delivery vehicles for genetic medicines, in an all-stock deal for $120 million upfront. Beam Therapeutics Inc (BEAM) Price Targets From Analysts. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. Should I buy or sell BEAM stock? Beam Therapeutics to offer 6.25 million shares in planned IPO priced at $15 to $17 each MarketWatch. Sell. Top ETF of December & Its Best Stocks. BEAM has been […] The stock had previously closed at $89.13. Wells Fargo & Company assumed coverage on shares of Beam Therapeutics in a report on Tuesday, February 16th. Over the past year the S&P 500 is higher by 11.50% while BEAM has risen 331.36%. 11-12 investing.com - Barclays (LON:BARC) analyst Gena Wang maintained a Buy rating on Beam Therapeutics on Tuesday, setting a price target of $47, which is approximately 24.73% above the present share price of $37.68. Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Analyst price target for BEAMBased on 5 analysts offering 12 month price targets for Beam Therapeutics Inc. Min Forecast. Get the latest Beam Therapeutics (BEAM) stock price quote with real-time news, financials, charts and other important investing information. In a report issued on February 16, Wells Fargo also initiated coverage with a Buy rating on the stock with a $145.00 price target. Beam Therapeutics Inc. (NASDAQ:BEAM) went down by -12.62% from its latest closing price compared to the recent 1-year high of $126.90. 0 analysts 0%. Beam’s proprietary base … Wells Fargo & Company started coverage on shares of Beam Therapeutics (NASDAQ:BEAM) in a report issued on Tuesday, Briefing.com reports. Beam Therapeutics is listed on the NASDAQ and employs 166 staff. During the day the price has varied from a low of $75.31 to a high of $86.75. Buy. 11-10 globenewswire.com - BEAM-201, an Off the Shelf … Last 30 Days. SA Breaking News . BEAM stock forecasts by analyst. GuideTx shareholders could also yield up to $320 million more in milestone payments. The extremes give us $42 and $145 for target low and target high price respectively. Beam Therapeutics Inc. Stock Forecast NASDAQ:BEAM Price Target and Analyst Ratings. 0 analysts 0%. BEAM Beam Therapeutics Announces Business and Pipeline Progress and Reports Third Quarter 2020 Financial Results. As such, BEAM has been trading 36.21% off suggested target high and -60.54% from its likely low. In recent trading, shares of Beam Therapeutics Inc have crossed above the average analyst 12-month target price of $37.50, changing hands for $38.29/share. 07:24 AM ET. Beam Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference. Approximately 980,142 shares were traded during mid-day trading, an increase of 16% from the average daily volume of 842,461 shares. Analyst Ratings. 12/24 11:10.